Visual abnormalities in a pregnancy following bromocriptin medication.
A patient with hyperprolactinemia, amenorrhea, and an enlarged sella turcica, but without galactorrhea, was treated with Bromocriptin to effect restoration of ovarian function. The subsequent pregnancy was without problems from an obstetric point of view, but visual field abnormalities developed progressively, leading to termination of the pregnancy in the 39th week. However, within 1 week after delivery, the field defects disappeared and the visual acuity returned to normal.
D000328:Adult; D000568:Amenorrhea / Q000175:diagnosis; D001971:Bromocriptine / Q000008:administration & dosage*; D002585:Cesarean Section; D004873:Ergolines / Q000008:administration & dosage*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007247:Infertility, Female / Q000175:diagnosis / Q000188:drug therapy; D007986:Luteinizing Hormone / Q000097:blood; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging; D011247:Pregnancy; D011248:Pregnancy Complications / Q000209:etiology*; D011388:Prolactin / Q000097:blood; D012658:Sella Turcica / Q000000981:diagnostic imaging; D013972:Thyrotropin / Q000097:blood; D014056:Tomography, X-Ray; D014786:Vision Disorders / Q000209:etiology*; D014792:Visual Acuity; D014794:Visual Fields
D004873:Ergolines; D001971:Bromocriptine; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin